Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm

Leuk Res. 2020 Nov:98:106456. doi: 10.1016/j.leukres.2020.106456. Epub 2020 Sep 22.

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States. Electronic address: john.mascarenhas@mssm.edu.

PMID: 33002673
DOI: 10.1016/j.leukres.2020.106456

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Disease-Free Survival
Female
Hematologic Neoplasms / drug therapy
Hematologic Neoplasms / mortality
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / mortality
Male
Middle Aged
Neoplasms, Second Primary* / drug therapy
Neoplasms, Second Primary* / mortality
Retrospective Studies
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Survival Rate

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax